Tall Stature: A Challenge for Clinicians
Open Access
- 5 April 2019
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pediatric Reviews
- Vol. 15 (1) , 10-21
Abstract
Clinicians generally use the term “tall stature” to define a height more than two standard deviations above the mean for age and sex. In most cases, these subjects present with familial tall stature or a constitutional advance of growth which is diagnosed by excluding the other conditions associated with overgrowth. Nevertheless, it is necessary to be able to identify situations in which tall stature or an accelerated growth rate indicate an underlying disorder. A careful physical evaluation allows the classification of tall patients into two groups: those with a normal appearance and those with an abnormal appearance including disproportion or dysmorphism. In the first case, the growth rate has to be evaluated and, if it is normal for age and sex, the subjects may be considered as having familial tall stature or constitutional advance of growth or they may be obese, while if the growth rate is increased, pubertal status and thyroid function should be evaluated. In turn, tall subjects having an abnormal appearance can be divided into proportionate and disproportionate syndromic patients. Before initiating further investigations, the clinician needs to perform both a careful physical examination and growth evaluation. To exclude pathological conditions, the cause of tall stature needs to be considered, although most children are healthy and generally do not require treatment to inhibit growth progression. In particular cases, familial tall stature subject can be treated by inducing puberty early and leading to a complete fusion of the epiphyses, so final height is reached. This review aims to provide proposals about the management of tall children.Keywords
This publication has 72 references indexed in Scilit:
- An Overgrowth Disorder Associated with Excessive Production of cGMP Due to a Gain-of-Function Mutation of the Natriuretic Peptide Receptor 2 GenePLOS ONE, 2012
- Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer riskThe Lancet Oncology, 2011
- A review of trisomy X (47,XXX)Orphanet Journal of Rare Diseases, 2010
- Efficacy and Safety of Percutaneous Epiphysiodesis Operation around the Knee to Reduce Adult Height in Extremely Tall Adolescent Girls and BoysInternational Journal of Pediatric Endocrinology, 2010
- Height, Body Mass Index, and Ovarian Cancer: A Pooled Analysis of 12 Cohort StudiesCancer Epidemiology, Biomarkers & Prevention, 2008
- A cluster of translocation breakpoints in 2q37 is associated with overexpression of NPPC in patients with a similar overgrowth phenotypeHuman Mutation, 2007
- Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocationHuman Mutation, 2007
- Combined Genome Scans for Body Stature in 6,602 European Twins: Evidence for Common Caucasian LociPLOS Genetics, 2007
- A Novel Mutation in FGFR3 Causes Camptodactyly, Tall Stature, and Hearing Loss (CATSHL) SyndromeThe American Journal of Human Genetics, 2006
- Genotype-Phenotype Associations in Sotos Syndrome: An Analysis of 266 Individuals with NSD1 AberrationsThe American Journal of Human Genetics, 2005